

Gastroenterology

Volume 169 / Issue 2

August 2025

www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER

Gastroenterology



IBD-Induced Depression. See article by Huang, et al, page 294 for additional information.

COMMENTARIES

183 Clinical Trials for Perianal Crohn's Disease: A Call for a Revised Approach

B. D. McDonald, N. K. Choi, J. A. Klein, J. St-Pierre, Z. D. Fine, and D. T. Rubin

188 Gut Feelings: The Critical Role of Interoception in Obesity and Disorders of Gut-Brain Interaction

L. Chang, C. A. Thaiss, Z. Knight, and S. Khalsa

DIVERSITY, EQUITY, AND INCLUSION IN GI

195 Gender Equity in Gastroenterology: Perspectives From the AGA Women's Committee on Current Frameworks and Future Directions

L. G. Rabinowitz, K. Newman, E. Boden, B. Burman, A. Khapra, A. L. Lucas, and AGA Women's Committee

MENTORING, EDUCATION, AND TRAINING CORNER

200 Demystifying the K Award

M. K. Kim, B. Chen, M. Martynenko, F. Rieder, R. Khedraki, A. Lembo, and J. J. Lin

EDITORIALS

205 Revisiting *Helicobacter pylori* Eradication: Evolving Evidence and Global Implications for Gastric Cancer Prevention

Z.-C. Liu and W.-Q. Li

See Wiklund A-K et al on page 244; See Jung YS et al on page 251; See Ford AC et al on page 261.

Video

Related article in CGH

Hot Papers From New Investigators

CME quiz

Editorial accompanies this article

Additional online content available

Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc., 1600 John F. Kennedy Boulevard, Suite 1600, Philadelphia, PA 1910, United States. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2025 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

207 The Gravity of a Unique Subcutaneous Anti-IL23 Induction Regimen*J. Wellens, E. Dreesen, and M. Ferrante*

See Hart A et al on page 308.

209 Improved deTXIon Is Harder When White Light Colonoscopy Gets a Stable Extended Depth of Field*G. B. Nigam and J. E. East*

See Toyoshima N et al on page 337.

212 Rifaximin Prophylaxis and Collateral Damage in Patients With Advanced Liver Disease*H. F. Chambers and C. A. Arias*

See Silvey S et al on page 349.

GASTRO CURBSIDE CONSULT**214 Unraveling a Case of Fatty Pancreas in a Child***J. Agarwal, H. Chandra, and R. Kapoor***218 Unraveling a Rare Case: Diarrhea, Alopecia, and Polyposis***H. Mizushima, H. Kinugasa, and M. Otsuka***ELECTRONIC GASTRO CURBSIDE CONSULT**For a full list, please see the table of contents online at www.gastrojournal.org.**GASTRO GRAND ROUNDS****221 Development of Acute Kidney Injury in a Patient With Alcohol-Related Cirrhosis: The Importance of Diagnosing the Cause of Acute Kidney Injury***A. Juanola, A. T. Ma, G. Cullaro, M. P. Alexander, A. S. Allegretti, and P. Ginès***REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY****230 Complications of Endoscopic Retrograde Cholangiopancreatography***M. Barakat, M. Saumoy, N. Forbes, and B. J. Elmunzer***ORIGINAL RESEARCH****Full Reports*****Helicobacter pylori*****244 Risk of Gastric Adenocarcinoma After Eradication of *Helicobacter pylori****A.-K. Wiklund, G. Santoni, J. Yan, C. Radkiewicz, S. Xie, H. Birgisson, E. Ness-Jensen, M. von Euler-Chelpin, J. H. Kaupila, and J. Lagergren*

See editorial on page 205.

Eradication treatment of the stomach bacterium *Helicobacter pylori* counteracts the risk of developing stomach cancer in a study from the 5 Nordic countries.**251 Preventive Effect of *Helicobacter pylori* Treatment on Gastric Cancer Incidence and Mortality: A Korean Population Study***Y. S. Jung, M. T. X. Tran, B. Park, and C. M. Moon*

See editorial on page 205.

Helicobacter pylori eradication can reduce the incidence and mortality rates of gastric cancer in adults of all ages, including older adults aged >70 years.

261 Eradication Therapy to Prevent Gastric Cancer in *Helicobacter pylori*-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies

A. C. Ford, Y. Yuan, J. Y. Park, D. Forman, and P. Moayyedi

See editorial on page 205.

The authors studied whether treating a bacterium in the human stomach, *Helicobacter pylori*, reduces risk of gastric cancer. Treatment of this bacterium reduced future occurrence of gastric cancer significantly in populations at high risk.

GI Cancer

277 Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem Cells

W. Xian, S. Wang, J. Xie, Y. Yamamoto, M. Khorrami, Y. Zhang, R. C. Montes, C. Desales, M. Khorrami, Z. Mory, A. Hoffman, A. Su, C. Nguyen, P. J. A. Davies, C. Stephan, S. Pan, W. Wu, Y. Liu, J. Siegelman, R. E. Waters, W. A. Ross, S. Song, M. Metersky, D. G. Beer, C. P. Crum, A. J. Stewart, M. Vincent, R. Russell, R. A. Izard, K. Y. Ho, J. Hung-Sen Lai, W. W. Bachovchin, J. A. Ajani, and F. D. McKeon

Stem cells sourced from precancerous lesions detail the 20-year evolution of esophageal cancer and support drug discovery for preemptive therapeutics.

Inflammatory Bowel Disease

294 Perforin Generated by CD8⁺ T Cells Exacerbates Inflammatory Bowel Disease-Induced Depression by Promoting CXCL9 Production in Intestinal Epithelial Cells

S. Huang, L. Pan, S. Pang, H. Guo, M. Li, Y. Tian, W. Shi, B. Liu, S. Wang, Z. Fan, Y. Zong, D. Tian, and D. Zhang

Perforin generated by colonic CD8⁺ T cells promotes intestinal epithelial cell CXCL9 production, which leads to neuronal endoplasmic reticulum stress in hippocampus and induces depression in inflammatory bowel disease.

308 Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study

A. Hart, R. Panaccione, F. Steinwurz, S. Danese, T. Hisamatsu, Q. Cao, T. Ritter, U. Seidler, M. Olurinde, M. L. Vetter, J. Yee, Z. Yang, Y. Wang, J. Johanns, C. Han, A. Sahoo, N. A. Terry, B. E. Sands, and G. D'Haens, on behalf of the GRAVITI Study Group

See editorial on page 207.

Guselkumab is a new treatment for improving Crohn's disease with a patient-friendly administration option. Guselkumab injections resulted in meaningful improvements in symptoms and the lining of the intestine.

Hepatobiliary

326 From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic Perspective

W.-Y. Liu, S. Huang, H. Ji, S. U. Kim, T. C.-F. Yip, G. L.-H. Wong, S. Petta, E. Tsochatzis, A. Nakajima, E. Bugianesi, G. B.-B. Goh, W.-K. Chan, M. Romero-Gomez, A. J. Sanyal, J. Boursier, H. Hagström, J. L. Calleja, V. de Lédinghen, P. N. Newsome, J.-G. Fan, M. Lai, L. Castéra, H. W. Lee, G. Pennisi, M. Yoneda, A. Armandi, K. K.-J. Teh, R. Gallego-Durán, A. Asgharpour, M. de Saint-Loup, Y. Shang, E. Llop, C. Fournier, S. Mahgoub, C. Lara-Romero, C. M. Canivet, M. S.-W. Chan, H. Lin, L.-L. Chen, G. Targher, C. D. Byrne, M. Du, V. Wai-Sun Wong, and M.-H. Zheng, on behalf of the VCTE-Prognosis Study Group

A continuous course of hepatic fat loss with fibrosis progression, referred to as "burning-out," was observed in patients with metabolic dysfunction-associated steatotic liver disease. These patients exhibited adverse outcomes in long-term follow-up.

Endoscopy

- 337** **The Efficacy of Texture and Color Enhancement Imaging Observation in the Detection of Colorectal Lesions: A Multicenter, Randomized Controlled Trial (deTXIon Study)**
N. Toyoshima, T. Sakamoto, K. Shinmura, K. Hotta, M. Misawa, N. Tamai, T. Uraoka, T. Matsuda, T. Shii, Y. Mizuguchi, H. Takamaru, K. Nakamura, Y. Kakugawa, M. Shiroyama, R. Kawagoe, K. Tsuchiya, H. Ike, A. Inaba, N. Minakata, K. Imai, K. Takada, S. Ito, K. Wakamura, S.-e. Kudo, K. Sumiyama, M. Ito, S. Tom, A. Fujimoto, and Y. Saito

See editorial on page 209.

When the latest model of the colonoscope is used, texture and color enhancement imaging showed similar overall adenoma detection capability as white light imaging and detected flatter lesions.

RESEARCH LETTERS

- 346** **Domain-Specific Effects of Sucrase-Isomaltase Genotype in Irritable Bowel Syndrome**
L. Torices, F. Bonfiglio, C. Esteban-Blanco, A. Zamfir-Taranu, H. Y. Naim, and M. D'Amato
- 349** **Rifaximin Does Not Increase the Rate of 30-Day Mortality in Patients With Cirrhosis and Daptomycin in Two National US-Based Cohorts**
S. Silvey, N. Patel, A. Khoruts, and J. S. Bajaj

See editorial on page 212.

- 352** **Remodelling the Colon With Ileal Properties to Treat Short Bowel Syndrome**
T. Liu, S. Li, J. O. Múnera, R. A. Shivdasani, X. Huang, and Q. Zhou

AGA SECTION

- 356** **Presentation of the AGA William Beaumont Prize in Gastroenterology to Evan S. Dellon, MPH**
R. S. Sandler and N. J. Shaheen
- 359** **Presentation of the AGA Distinguished Achievement Award in Basic Science to Eugene Chang, MD, AGAF**
R. Balfour Sartor, M. C. Rao, and A. Ma

GASTRO DIGEST

- 363** **Periprocedural Risks Associated With GLP-1 Receptor Agonists**
R. Khan
- 363** **The Safety and Efficacy of Guselkumab for the Treatment of Moderate to Severely Active Ulcerative Colitis**
R. Khanna
- 364** **Metagenome-Informed Metaproteomics: A New Frontier in Gut Host-Microbe-Diet Analysis**
E. Wine
- 365** **Sweet Tooth? Blame It on Your Dessert Brain!**
C. Y. Q. Lee and K. G. Margolis

CORRESPONDENCE

- 367** **Pesticides and Inflammatory Bowel Disease: A Critical Look at the Hidden Gaps in the Exposome-Disease Link**
Y. Jiao and Y. Ma

- 367 Reply**
M. Agrawal, V. Midya, and J.-F. Colombel
- 369 Further Insights Into the Roles of Gut Microbiota in Immune Checkpoint Inhibitor Efficacy in Patients With Gastric Adenocarcinoma**
X. Zhu
- 369 Reply**
H. Sokol and D. Tougeron
- 370 Gut Archaea in Colorectal Cancer Diagnosis and Ecology**
A. Zuo, Y. Ba, S. Liu, D. Shan, and Z. Liu
- 371 Critical Analysis of Random Forest Feature Selection: Implications for Gut Microbiome Cancer Research**
Y. Takefuji
- 372 Methanogens in Colorectal Cancer: Association or Causation?**
J. Bu, X. Zhu, and H. Zhang
- 373 Reply**
T. Li, O. O. Coker, and J. Yu
- 374 Endoscopic Retrograde Cholangiopancreatography-Related Adverse Events: Reflections on Indication Criteria and Data Accuracy**
L. Yang, J. Tang, C. Yang, G. Liu, and L. Yuan
- 375 Comments on "Adverse Events Associated With Endoscopic Retrograde Cholangiopancreatography: Systematic Review and Meta-Analysis"**
Y. He, H. He, and Y. Xie
- 375 Risk of Death Associated With Endoscopic Retrograde Cholangiopancreatography: How to Interpret and Mitigate?**
S. J. Mahapatra, M. L. Freeman, and P. K. Garg
- 376 Reply**
K. Bishay, Z. W. Meng, and N. Forbes
- 377 Is PAaM Truly the Answer for Precise Hepatocellular Carcinoma Risk Stratification?**
Y. Zheng and D. Shan
- 378 Considerations on the Clinical Translation and Statistical Rigor of the PAaM Score for Hepatocellular Carcinoma Risk Stratification**
L. Bao, B. Jiang, and Y. Ye
- 379 Reply**
N. Fujiwara, A. G. Singal, and Y. Hoshida

- 381 The Importance of the Mesentery in the Pathophysiology of Crohn's Disease**
M. Kelm and S. Flemming
- 382 Creeping Fat and Muscle Hyperplasia in Crohn's Disease: A Critical Mechanistic Link for Stricture Formation**
Y. Zhang, Q. Ran, X. Tang, Y. Wang, and Y. Cao
- 382 Reply**
J. C. Coffey and M. Devine
- 383 Reply**
W. Liu and F. Rieder
- 384 Regarding "Fecal Hemoglobin Levels in Prior Negative Screening and Detection of Colorectal Neoplasia: A Dose-Response Meta-Analysis"**
G. Antonelli, L. Frazzoni, L. Fuccio, and C. Hassan
- 385 Comments on "Fecal Hemoglobin Levels in Prior Negative Screening and Detection of Colorectal Neoplasia: A Dose-Response Meta-Analysis"**
Z. Wang, H. Shi, G. Zhang, and H. Wang
- 386 Statistical Optimization in Dose-Response Meta-Analysis: Advancing FIT-Based Colorectal Neoplasia Risk Prediction**
Y. He, R. Tao, and W. Guo
- 387 Reply**
D. M. N. van den Berg, L. de Jonge, and E. Toes-Zoutendijk
- 389 Corrigenda**

Access to the full content of Gastroenterology Online is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

Your Account Number

Sample
mailing
label

GAST0000101864
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

1GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001